-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Advaxis (OTCMKTS:ADXS) & NRx Pharmaceuticals (NASDAQ:NRXP) Financial Review
Advaxis (OTCMKTS:ADXS) & NRx Pharmaceuticals (NASDAQ:NRXP) Financial Review
Advaxis (OTCMKTS:ADXS – Get Rating) and NRx Pharmaceuticals (NASDAQ:NRXP – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.
Institutional and Insider Ownership
6.7% of Advaxis shares are owned by institutional investors. Comparatively, 3.9% of NRx Pharmaceuticals shares are owned by institutional investors. 0.3% of Advaxis shares are owned by company insiders. Comparatively, 27.1% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Get Advaxis alerts:Profitability
This table compares Advaxis and NRx Pharmaceuticals' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Advaxis | N/A | -42.66% | -36.09% |
NRx Pharmaceuticals | N/A | -352.99% | -197.86% |
Volatility and Risk
Advaxis has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.Analyst Recommendations
This is a summary of recent recommendations for Advaxis and NRx Pharmaceuticals, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Advaxis | 0 | 0 | 0 | 0 | N/A |
NRx Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
NRx Pharmaceuticals has a consensus price target of $2.00, indicating a potential upside of 196.21%. Given NRx Pharmaceuticals' higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Advaxis.
Earnings & Valuation
This table compares Advaxis and NRx Pharmaceuticals' revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Advaxis | $3.24 million | 1.89 | -$17.86 million | ($0.10) | -33.80 |
NRx Pharmaceuticals | N/A | N/A | -$93.06 million | ($0.81) | -0.83 |
Advaxis has higher revenue and earnings than NRx Pharmaceuticals. Advaxis is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Advaxis beats NRx Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About Advaxis
(Get Rating)
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
About NRx Pharmaceuticals
(Get Rating)
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
Advaxis (OTCMKTS:ADXS – Get Rating) and NRx Pharmaceuticals (NASDAQ:NRXP – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.
Advaxis(OTCMKTS:ADXS-GET Rating)和NRX PharmPharmticals(納斯達克:NRXP-GET Rating)都是小盤醫療公司,但哪一家更好?我們將根據這兩家公司的風險、盈利能力、收益、股息、分析師建議、估值和機構持股的強弱進行比較。
Institutional and Insider Ownership
機構和內部人持股
6.7% of Advaxis shares are owned by institutional investors. Comparatively, 3.9% of NRx Pharmaceuticals shares are owned by institutional investors. 0.3% of Advaxis shares are owned by company insiders. Comparatively, 27.1% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Advaxis 6.7%的股份由機構投資者持有。相比之下,NRX製藥3.9%的股份由機構投資者持有。Advaxis 0.3%的股份由公司內部人士持有。相比之下,NRX製藥公司27.1%的股份由公司內部人士持有。強大的機構持股表明,捐贈基金、對衝基金和大型基金管理公司相信,一家公司的長期表現將好於大盤。
Profitability
盈利能力
This table compares Advaxis and NRx Pharmaceuticals' net margins, return on equity and return on assets.
此表比較了Advaxis和NRX製藥公司的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Advaxis | N/A | -42.66% | -36.09% |
NRx Pharmaceuticals | N/A | -352.99% | -197.86% |
淨利潤率 | 股本回報率 | 資產回報率 | |
前進軸 | 不適用 | -42.66% | -36.09% |
NRX製藥公司 | 不適用 | -352.99% | -197.86% |
Volatility and Risk
波動性和風險
Analyst Recommendations
分析師建議
This is a summary of recent recommendations for Advaxis and NRx Pharmaceuticals, as reported by MarketBeat.com.
這是MarketBeat.com報道的Advaxis和NRX製藥公司最近建議的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Advaxis | 0 | 0 | 0 | 0 | N/A |
NRx Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
前進軸 | 0 | 0 | 0 | 0 | 不適用 |
NRX製藥公司 | 0 | 0 | 1 | 0 | 3.00 |
NRx Pharmaceuticals has a consensus price target of $2.00, indicating a potential upside of 196.21%. Given NRx Pharmaceuticals' higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Advaxis.
NRX製藥公司的共識目標價為2.00美元,表明潛在上漲196.21。考慮到NRX製藥更有可能上行,分析師顯然認為NRX製藥比Advaxis更有利。
Earnings & Valuation
收益與估值
This table compares Advaxis and NRx Pharmaceuticals' revenue, earnings per share and valuation.
該表格比較了Advaxis和NRX製藥公司的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Advaxis | $3.24 million | 1.89 | -$17.86 million | ($0.10) | -33.80 |
NRx Pharmaceuticals | N/A | N/A | -$93.06 million | ($0.81) | -0.83 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
前進軸 | 324萬美元 | 1.89 | -1,786萬元 | ($0.10) | -33.80 |
NRX製藥公司 | 不適用 | 不適用 | -9,306萬元 | ($0.81) | -0.83 |
Advaxis has higher revenue and earnings than NRx Pharmaceuticals. Advaxis is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Advaxis的收入和收益高於NRX製藥公司。Advaxis的市盈率低於NRX PharmPharmticals,這表明它目前是兩隻股票中更負擔得起的一隻。
Summary
摘要
Advaxis beats NRx Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
Advaxis在兩隻股票比較的11個因素中有7個擊敗了NRX製藥公司。
About Advaxis
關於Advaxis
(Get Rating)
(獲取評級)
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Advaxis,Inc.是一家臨牀階段的生物技術公司,專注於在美國發現、開發和商業化專有的單核細胞增生性李斯特菌(LM)技術抗原遞送產品。該公司正在開發ADXS-PSA,這是用於治療轉移性前列腺癌的第二階段臨牀試驗;ADXS-503,用於治療非小細胞肺癌;以及ADXS-504,用於治療前列腺癌。它還在進行以下領域的LM技術免疫療法的臨牀研究:疾病熱點/現成的新抗原導向療法;人乳頭瘤病毒相關癌症;以及前列腺癌。該公司與默克公司、OS Treateuies公司、Aratana治療公司、Biocon有限公司、Global BioPharma Inc.、Knight Treateutics Inc.以及其他公司建立了合作和夥伴關係。Advaxis,Inc.成立於2002年,總部設在新澤西州的蒙茅斯路口。
About NRx Pharmaceuticals
關於NRX製藥公司
(Get Rating)
(獲取評級)
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NRX製藥公司是一家臨牀階段的製藥公司,開發用於治療中樞神經系統疾病和危及生命的肺部疾病的新療法。該公司的產品包括已經完成了治療新冠肺炎相關呼吸衰竭的IIb/III期臨牀研究的研究藥物ZYESAMI,以及用於治療急性自殺行為/意念和亞急性自殺意念和行為患者的雙相抑鬱的口服療法。該公司成立於2015年,總部設在特拉華州威爾明頓。
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
接受Advaxis Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Advaxis和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧